StemCell Therapy

GOSSELIES, Wallonia, Belgium, September 19, 2022--(BUSINESS WIRE)--Regulatory News:

TheraVet (ISIN: BE0974387194 - ticker: ALVET) (Paris:ALVET), a pioneering company in the management of osteoarticular diseases in pets, announced today its participation in the annual congress of the European Society of Veterinary Orthopaedics and Traumatology (ESVOT) which will be held from 21 to 24 September at the Acropolis in Nice, France.

With nearly 1000 participants, this event is the largest specialised congress in veterinary orthopaedics and traumatology in Europe, bringing together high-quality international speakers and therefore represents a prime showcase for the Company. ESVOT is chaired by Pr. Marc Balligand, who is also the President of the Scientific Advisory Board of TheraVet.

The Company will be particularly well represented with 3 scientific communications. The results obtained through close collaborations with renowned veterinarians will be presented during this conference, proof of the growing interest of the veterinary community in the Company's products:

"Percutaneous cementoplasty as a palliative treatment for dogs with osteosarcoma using a new self-setting bone substitute"Thursday 22 September 2022 at 8:00 pmPoster presentation by Dr. A. Villamonte Chevalier (DVM, PhD), Vet Technical Manager at TheraVet

"Microwave ablation as part of limb sparing multimodal therapy in dog with appendicular osteosarcoma"Saturday 24 September 2022 at 12:10 pmOral presentation by Dr. D. Jacques (DVM, DIPL. ECVS) Clinique Vtrinaire Occitanie, France

"Efficacy and safety assessment of a self-setting bone substitute (alpha-TCP) as an efficient alternative to autografts"Saturday 24 September 2022 at 5:30 pmOral presentation by Dr. G. Ragetly (DVM, PhD, Dipl. ACVS, DIPL. ECVS), CHV Frgis, France

The Company will also have a strong commercial presence for its BIOCERA-VET products, including:

- Drylab sessions allowing veterinarians to test and evaluate the performance of the products,- Videos demonstrating the use of the products in real clinical cases,- Coupons, promotional documents

Story continues

About TheraVet SATheraVet is a veterinary biotechnology company specialising in osteoarticular treatments for companion animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from joint and bone diseases. For pet owners, the health of their pets is a major concern and TheraVets mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth Paris and Brussels, has its head office in Belgium (Gosselies) with a US subsidiary in Texas.For more information, visit the TheraVet website or follow us on LinkedIn / Facebook / Twitter

About BIOCERA-VETIn close collaboration with an international scientific board, THERAVET has developed a new line of calcium-phosphate and biological bone substitutes, BIOCERA-VET. BIOCERA-VET is a full range of innovative, easy-to-use, efficient & cost-effective bone substitutes indicated in bone surgeries where a bone graft is required and as a palliative alternative in the management of canine osteosarcoma. Based on extremely promising clinical results, this line offers the possibility of a better, more convenient and more efficient orthopedic surgery.

BIOCERA-VET is declined in different lines:

BIOCERA-VET BONE SURGERY RTU, ready-to-use highly injectable self-hardening calcium-phosphate cement

BIOCERA-VET SMARTGRAFT, a naturally osteoconductive bone graft

BIOCERA-VET GRANULES, an affordable biocompatible calcium-phosphate bone substitute

BIOCERA-VET OSTEOSARCOMA RTU, a ready-to-use highly injectable calcium-phosphate bone substitute for cementoplasty

For more information, visit BIOCERA-VET website.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220918005014/en/

Contacts

TheraVet Chief Operating OfficerSabrina Enainvestors@thera.vet Tel: +32 (0) 71 96 00 43

Chief Corporate OfficerJulie Winandinvestors@thera.vet

NewCap Investor Relations and Financial CommunicationsTho Martin / Hugo Willeferttheravet@newcap.eu Tel: +33 (0)1 44 71 94 94

Press RelationsArthur Rouilltheravet@newcap.eu Tel: +33 (0)1 44 71 00 15

NewCap Belgique Press RelationsLaure-Eve Monfortlemonfort@thera.vet Tel: + 32 (0) 489 57 76 52

Excerpt from:
TheraVet Announces Its Participation in the 2022 ESVOT Congress With 3 Scientific Communications - Yahoo Finance

This entry was posted on September 20, 2022 at 2:02 am and is filed under Veterinary Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |